Bayer wins China approval. Bayer stock stays 22.10 percent below EUR 61.00 target

Published on 10/29/2026 at 14:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Asundexian cut ischemic stroke by 26 percent in Bayer's trial. Bayer stock trades at EUR 47.52 on October 29, 2026, 3.24 percent above Xetra close.

What changes for Bayer

China authorized asundexian as the first Factor XIa inhibitor approved worldwide.
Darolutamide reduced the combined risk of metastasis or death by 58 percent in an interim Phase III analysis.
Bayer will publish third-quarter 2026 results on November 3, 2026.

Bayer, DE000BAY0017, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) remains 22.10 percent below JPMorgan's EUR 61.00 target, while a fresh China approval adds to the pipeline case. On October 26, 2026, Bayer said Chinese regulators authorized asundexian under the brand name Sunharbo.

Approval adds commercial optionality

The Chinese decision gives Bayer its first worldwide approval for a Factor XIa inhibitor. The authorization covers stroke-risk reduction after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

Bayer said the OCEANIC-STROKE study enrolled 12,327 participants and showed a 26 percent reduction in ischemic stroke when asundexian was combined with antiplatelet therapy. The company also reported similar rates of all bleeding events between the treatment groups.

Why the pipeline still needs proof

The market conclusion is more measured than the approval headline: the stock remains below the optimistic target, so investors are still pricing execution risk alongside pipeline progress. JPMorgan analyst Richard Vosser kept a Buy rating and a EUR 61.00 target on October 26, 2026, according to MarketScreener.

A second Bayer catalyst remains experimental. In an October 24, 2026 release, Bayer said interim DASL-HiCaP results showed a 58 percent reduction in the combined risk of metastasis or death, with four-year metastasis-free survival at 95 percent versus 88 percent for placebo. The treatment setting is not yet approved.

November brings the next test

Bayer's next scheduled reporting checkpoint is November 3, 2026. The company will publish third-quarter results at 7:30 a.m. CET and hold its investor video call at 2:00 p.m. CET, according to its investor event page.

Stock remains below the bullish target

At Lang & Schwarz, Bayer was trading intraday at EUR 47.52 on October 29, 2026 at 2:36 p.m. CET, up 3.24 percent versus the Xetra close of October 28, 2026 at EUR 46.03. The price is above the cautious EUR 46.00 target cited in recent coverage but remains below JPMorgan's EUR 61.00 target.